Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2020-01-30

FDA Approved: AVODART — Supplemental Application (Waylis Therapeutics LLC)

View source ↗

Summary

FDA approved a supplemental application for AVODART (dutasteride) filed by Waylis Therapeutics LLC, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Avodart (dutasteride)

Snippet

SUPPL AP for AVODART (DUTASTERIDE)